National Health (Ceasing of Co-marketed Brands) Determination 2013 (No. 1) (No. PB 20 of 2013) (Cth)
PB 20 of 2013
National Health (Ceasing of Co-marketed Brands) Determination 2013 (No. 1)1
National Health Act 1953
___________________________________________________________________________
I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, determine under subsection 84AE(3B) of the National Health Act 1953 (“the Act”) that the brands of pharmaceutical items specified in columns 2 and 3 of an item specified in column 1 of the Schedule cease to be co-marketed brands of a pharmaceutical item.
This instrument commences on 1 April 2013;
Dated 27 March 2013
ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health and Ageing
Schedule
| Column 1 | Column 2 | Column 3 | ||||||
| Item | Listed brand of pharmaceutical item | Listed brand of pharmaceutical item | ||||||
| Brand | Drug | Form | Manner of administration | Brand | Drug | Form | Manner of administration | |
| 1 | Avapro | Irbesartan | Tablet 75 mg | Oral | Karvea | Irbesartan | Tablet 75 mg | Oral |
| 2 | Avapro | Irbesartan | Tablet 150 mg | Oral | Karvea | Irbesartan | Tablet 150 mg | Oral |
| 3 | Avapro | Irbesartan | Tablet 300 mg | Oral | Karvea | Irbesartan | Tablet 300 mg | Oral |
Note
1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See
0
0
0